First KRAS/PRMT5 combination data reports 92% ORR

Early clinical data for a KRAS inhibitor plus PRMT5 combination suggests combinations may define the next phase of RAS-targeted cancer therapy

Last year, we reported that KRAS+PRMT5 is synergistic in MTAP-null PDAC ( https:// doi.org/10.1158/0008-5 472.CAN-25-1464 …). Today, the first clinical data for a KRAS/PRMT5 combination was reported, with an incredible 92% ORR. RAS inhibit